The efficacy and safety of Capivasertib (AZD5363) in the treatment of patients with solid tumor : a systematic review and meta-analysis of randomized clinical trials
OBJECTIVE: To evaluate the clinical efficacy and safety of Capivasertib on patients with solid tumors.
METHODS: Data from four RCTs were pooled to create a systematic review and meta-analysis focusing on Capivasertib-treated patients with solid tumor. Progression-free survival (PFS) and adverse events (AE) were the primary outcomes.
RESULTS: A total of 540 individuals from four RCTs were included. The analysis showed that Capivasertib improved PFS for the ITT population with an HR of 0.75 (95% CI = 0.62-0.90, p = 0.002), whereas it did not show improvement in PFS of the PI3K/AKT/PTEN-altered group with an HR = 0.61 (95% CI = 0.32-1.16, p = 0.13). The analysis also showed that Capivasertib improved OS for the ITT population with an HR = 0.61 (95% CI = 0.47-0.78, p = 0.0001). For safety, four studies were included; statistical differences between Capivasertib and placebo were found in discontinuation of Capivasertib due to toxicity or AE (RR = 2.37, 95% CI = 1.37-4.10, p = 0.002).
CONCLUSION: Capivasertib plus chemotherapy or hormonal therapy combination has shown promising antitumor efficacy and promising safety profile in the treatment of individuals with solid tumor.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Expert opinion on drug safety - 22(2023), 9 vom: 26. Juli, Seite 799-805 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abushanab, Aws Khalid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AZD5363 |
|---|
| Anmerkungen: |
Date Completed 02.11.2023 Date Revised 02.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14740338.2023.2218085 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357266722 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357266722 | ||
| 003 | DE-627 | ||
| 005 | 20231226072220.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14740338.2023.2218085 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357266722 | ||
| 035 | |a (NLM)37224269 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abushanab, Aws Khalid |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The efficacy and safety of Capivasertib (AZD5363) in the treatment of patients with solid tumor |b a systematic review and meta-analysis of randomized clinical trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2023 | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To evaluate the clinical efficacy and safety of Capivasertib on patients with solid tumors | ||
| 520 | |a METHODS: Data from four RCTs were pooled to create a systematic review and meta-analysis focusing on Capivasertib-treated patients with solid tumor. Progression-free survival (PFS) and adverse events (AE) were the primary outcomes | ||
| 520 | |a RESULTS: A total of 540 individuals from four RCTs were included. The analysis showed that Capivasertib improved PFS for the ITT population with an HR of 0.75 (95% CI = 0.62-0.90, p = 0.002), whereas it did not show improvement in PFS of the PI3K/AKT/PTEN-altered group with an HR = 0.61 (95% CI = 0.32-1.16, p = 0.13). The analysis also showed that Capivasertib improved OS for the ITT population with an HR = 0.61 (95% CI = 0.47-0.78, p = 0.0001). For safety, four studies were included; statistical differences between Capivasertib and placebo were found in discontinuation of Capivasertib due to toxicity or AE (RR = 2.37, 95% CI = 1.37-4.10, p = 0.002) | ||
| 520 | |a CONCLUSION: Capivasertib plus chemotherapy or hormonal therapy combination has shown promising antitumor efficacy and promising safety profile in the treatment of individuals with solid tumor | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AZD5363 | |
| 650 | 4 | |a Capivasertib | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a solid tumor | |
| 650 | 7 | |a capivasertib |2 NLM | |
| 650 | 7 | |a WFR23M21IE |2 NLM | |
| 650 | 7 | |a Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 700 | 1 | |a Mousa, Mahmoud Taysir |e verfasserin |4 aut | |
| 700 | 1 | |a Mustafa, Mus'ab Theeb |e verfasserin |4 aut | |
| 700 | 1 | |a Qawaqzeh, Rana Ahmed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d 2002 |g 22(2023), 9 vom: 26. Juli, Seite 799-805 |w (DE-627)NLM126588422 |x 1744-764X |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:9 |g day:26 |g month:07 |g pages:799-805 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14740338.2023.2218085 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 9 |b 26 |c 07 |h 799-805 | ||